Vasa Therapeutics is a San Diego-based, private biotechnology company committed to the discovery and development of therapeutics that target pathophysiology of cardiovascular aging.
Vasa Therapeutics has three active preclinical programs:
1. VS-041 is the first personalized medicine-based treatment of HFpEF. VS-041 shows robust reduction of cardiac fibrosis in a preclinical HFpEF model and inhibits release of signaling collagen fragments, such as PRO-C6, that mediate fibroinflammatory responses and are biomarkers of worse outcomes in HFpEF patients. Phase 1 clinical trial of VS-041 is planned for 2024.
2. Long acting apelin peptide analogs for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease. As a monotherapy, long acting apelin agonists could also be beneficial in muscle atrophy, heart failure, chronic kidney disease, and peripheral artery disease.
3. A best-in-class inhibitor of CamKIId for heart failure and life-threatening arrhythmias.
Company Details
- Employees
- 8
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.vasatherapeutics.com
Vasa Therapeutics Questions
Vasa Therapeutics's website is http://www.vasatherapeutics.com
Vasa Therapeutics's LinkedIn profile is https://www.linkedin.com/company/vasa-therapeutics
Vasa Therapeutics has
8 employees.
View email and phone details for 8
employees at Vasa Therapeutics.
Vasa Therapeutics's industry is
Biotechnology Research
Vasa Therapeutics's top competitors are
Ferdia Therapeutics Llc,
Seal Rock Therapeutics,
Orphinic Scientific,
Crinetics Pharmaceuticals,
Travere Therapeutics,
Exithera Pharmaceuticals Llc,
Btb Therapeutics, Inc.,
Artery Therapeutics, Inc.,
Biolexis Therapeutics, Inc.,
Quotient Sciences.
Vasa Therapeutics's categories are Biotechnology Research
Vasa Therapeutics's founding year is 2019
